A phase 3, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (CheckMate 7DX)

Mapping Intimacies ◽

10.26226/morressier.613756f1842293c031b5830d ◽

2021 ◽

Author(s):

Karim Fizazi

Keyword(s):

Prostate Cancer ◽

Double Blind Trial ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Blind Trial ◽

Castration Resistant

Download Full-text

690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2084 ◽

2020 ◽

Vol 31 ◽

pp. S546

Author(s):

C.G. Drake ◽

F. Saad ◽

W.R. Clark ◽

M. Ciprotti ◽

B. Sharkey ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Double Blind Trial ◽

Castration Resistant Prostate Cancer ◽

Double Blind ◽

Blind Trial ◽

Castration Resistant

Download Full-text

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

10.1016/s0140-6736(21)00580-8 ◽

2021 ◽

Vol 398 (10295) ◽

pp. 131-142

Author(s):

Christopher Sweeney ◽

Sergio Bracarda ◽

Cora N Sternberg ◽

Kim N Chi ◽

David Olmos ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant

Download Full-text

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30898-2 ◽

2019 ◽

Vol 20 (4) ◽

pp. 556-569 ◽

Author(s):

Bertrand Tombal ◽

Fred Saad ◽

David Penson ◽

Maha Hussain ◽

Cora N Sternberg ◽

...

Keyword(s):

Prostate Cancer ◽

Patient Reported Outcomes ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Patient Reported

Download Full-text

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Download Full-text

Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.tps5081 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS5081-TPS5081 ◽

Author(s):

James L. Gulley ◽

Jeannie Lorraine Giacchino ◽

James Bradley Breitmeyer ◽

Alexis J. Franzusoff ◽

Dennis Panicali ◽

...

Keyword(s):

Prostate Cancer ◽

Efficacy Study ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant

Download Full-text

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70474-7 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1397-1406 ◽

Author(s):

Peter Hoskin ◽

Oliver Sartor ◽

Joe M O'Sullivan ◽

Dag Clement Johannessen ◽

Svein I Helle ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Subgroup Analysis ◽

Efficacy And Safety ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Download Full-text

C176 PROLONGED BONE METASTASIS-FREE SURVIVAL IN MEN WITH CASTRATE-RESISTANT PROSTATE CANCER RECEIVING DENOSUMAB: RESULTS FROM A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL

European Urology Supplements ◽

10.1016/s1569-9056(11)61756-9 ◽

2011 ◽

Vol 10 (9) ◽

pp. 656

Author(s):

T. Borkowski ◽

M. Smith ◽

F. Saad ◽

R. Coleman ◽

N. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastasis ◽

Double Blind Trial ◽

Phase 3 ◽

Double Blind ◽

Free Survival ◽

Blind Trial ◽

Castrate Resistant Prostate Cancer ◽

Castrate Resistant

Download Full-text

Re: Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients with Castration-Resistant Prostate Cancer and Bone Metastases: Results from a Phase 3, Double-Blind, Randomised Trial

The Journal of Urology ◽

10.1016/j.juro.2014.12.077 ◽

2015 ◽

Vol 193 (3) ◽

pp. 847-848

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Randomised Trial ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Download Full-text

Faculty Opinions recommendation of Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.740905744.793589416 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant

Download Full-text

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

Download Full-text